一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Journal of Nanobiotechnology >>article
Journal of Nanobiotechnology

Journal of Nanobiotechnology

IF: 10.6
Download PDF

Injectable photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered exosomes for osteoarthritis therapy

Published:21 August 2023 DOI: 10.1186/s12951-023-02050-7 PMID: 37605203
Junlai Wan,?Zhiyi He,?Renpeng Peng,?Xiaopei Wu,?Ziqing Zhu,?Jiarui Cui,?Xiaoxia Hao,?Anmin Chen,?Jiaming Zhang,?Peng Cheng

Abstract

Osteoarthritis (OA) is a common degenerative joint disease urgently needing effective treatments. Bone marrow mesenchymal stromal cell-derived exosomes (Exo) are considered good drug carriers whereas they have limitations such as fast clearance and low retention. This study aimed to overcome the limitations of Exo in drug delivery using multiple strategies. Novel photocrosslinking spherical gelatin methacryloyl hydrogel (GelMA)-encapsulated cartilage affinity WYRGRL (W) peptide-modified engineered Exo were developed for OA treatment and the performance of the engineered Exo (W-Exo@GelMA) loaded with a small inhibitor LRRK2-IN-1 (W-Exo-L@GelMA) was investigated in vitro and in vivo. The W-Exo-L@GelMA showed an effective targeting effect on chondrocytes and a pronounced action on suppressing catabolism and promoting anabolism in vitro. Moreover, W-Exo-L@GelMA remarkably inhibited OA-related inflammation and immune gene expression, rescuing the IL-1β-induced transcriptomic responses. With enhanced retention in the joint, W-Exo-L@GelMA demonstrated superior anti-OA activity and cartilage repair ability in the OA murine model. The therapeutic effect was validated in the cultured human OA cartilage. In conclusion, photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered Exo exhibit notable potential in OA therapy. Engineering Exo by a series of strategies enhanced the targeting ability and retention and cartilage-targeting and Exo-mediated drug delivery may offer a novel strategy for OA treatment.Clinical trial registration:?Not applciable.

Substances (5)

Materials Related products
Procduct Name CAS Molecular Formula Supplier Price
LRRK2-IN-1 1234480-84-2 C31H38N8O3 124 suppliers $27.00-$7200.00
LRRK2-IN-1 1234480-84-2 C31H38N8O3 124 suppliers $27.00-$7200.00
LRRK2-IN-1 1234480-84-2 C31H38N8O3 124 suppliers $27.00-$7200.00
LRRK2-IN-1 1234480-84-2 C31H38N8O3 124 suppliers $27.00-$7200.00

Similar articles

IF:10

Localized Hydrogel Microspheres for Osteoarthritis Treatment: Recruitment and Differentiation of Stem Cells

Advanced Healthcare Materials Qiming Pang, Zhuolin Chen,etc Published: 28 November 2024
IF:10.7

Antibacterial betaine modified chitosan-based hydrogel with angiogenic property for photothermal enhanced diabetic wound repairing

Carbohydrate Polymers Kaiyue Zhang, Jingjing Zhu,etc Published: 19 November 2024
IF:8.8

Celecoxib for osteoarthritis.

Cochrane Database of Systematic Reviews Livia Puljak,?Ana Marin,etc Published: 22 May 2017
玉环县| 大港区| 高邮市| 乡宁县| 梅河口市| 满洲里市| 刚察县| 嵊泗县| 平度市| 昌吉市| 同江市| 新宁县| 溧水县| 兴山县| 平原县| 达日县| 兰西县| 沛县| 正镶白旗| 嘉禾县| 锦州市| 龙江县| 阿克陶县| 元阳县| 聂拉木县| 天镇县| 石泉县| 万载县| 嘉善县| 钟祥市| 高尔夫| 慈溪市| 娄底市| 安国市| 肇源县| 体育| 晋中市| 会昌县| 义马市| 邮箱| 岐山县|